2016 Drug Development Pharmaceutical Companies 
European Pharmaceutical Review
AUGUST 9, 2023
While injectable biologic therapies are an effective option for CSU that is uncontrolled by these drugs, less than 20 percent of patients worldwide are treated with them, according to a 2016 British Journal of Dermatology paper and research shared by Novartis. There were 470 participants in the REMIX-1 study.
Pharma Marketing Network
MAY 15, 2023
Big data has become an increasingly important tool for businesses across various industries, and the pharmaceutical industry is no exception. However, the use of big data in pharmaceutical marketing also poses significant challenges that must be considered. Another challenge is the sheer volume of data that companies must manage.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
JUNE 29, 2022
Almost 40 years since it was instituted, some have described the FDA’s orphan drug program, which is meant to foster innovation, as “ one of the most successful US legislative actions in recent history ”. Others judge its success based on the fact that 95% of rare diseases still have no available therapies and patient needs remain unmet.
Pharma Marketing Network
MARCH 23, 2023
Big data has become an increasingly important tool for businesses across various industries, and the pharmaceutical industry is no exception. However, the use of big data in pharmaceutical marketing also poses significant challenges that must be considered. Another challenge is the sheer volume of data that companies must manage.
European Pharmaceutical Review
JULY 4, 2024
The second was crofelemer, Mytesi , an indicator drug for HIV-associated diarrhoea extracted from the blood-red latex of the South American croton tree. 2 It was first approved as Fulyzaq in December 2012 and in October 2016, Napo Pharmaceuticals launched the new brand, Mytesi. 3 Is two too few? BMB Reports. 2017;50(3):111–6.
STAT
MARCH 25, 2024
WASHINGTON — The Supreme Court on Tuesday will hear opening arguments in an abortion medication case that pharmaceutical companies warn could upend the industry and paralyze new drug development.
European Pharmaceutical Review
OCTOBER 19, 2022
Patents are often described as the ‘lifeblood’ of pharmaceutical companies. 1 However, patent protection for pharmaceutical products is an economic trade-off between providing monopoly rights that incentivise development of future products and permitting higher drug prices to recoup the investment. 26 April, 2016.
Expert insights. Personalized for you.
94 
Let's personalize your content